Elsevier

The Lancet

Volume 367, Issue 9522, 13–19 May 2006, Pages 1560-1561
The Lancet

Comment
Global framework on essential health R&D

https://doi.org/10.1016/S0140-6736(06)68672-8Get rights and content

References (13)

There are more references available in the full text version of this article.

Cited by (146)

  • Synthesis of heteroleptic pentavalent antimonials bearing heterocyclic cinnamate moieties and their biological studies

    2018, Inorganica Chimica Acta
    Citation Excerpt :

    Leishmaniasis is considered by – WHO as one of the six epidemic diseases worldwide with limited number of available drugs. So, the synthesis of new drugs for the neglected disease has become a global concern [6]. In 1940s, trivalent antimonials were replaced by the two more effective pentavalent antimonials i.e., sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®).

View all citing articles on Scopus
View full text